<DOC>
	<DOCNO>NCT02155322</DOCNO>
	<brief_summary>This study ass safety Pegylated Interferon Alfa-2b ( PEG-IFN ) adjuvant treatment melanoma .</brief_summary>
	<brief_title>A Phase II Study Pegylated Interferon Alfa-2b Adjuvant Treatment Melanoma Subjects Russia ( MK-4031-400 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Competent selfadminister subcutaneous injection PEGIFN Histologically document involved regional lymph node primary cutaneous melanoma unknown primary , meeting study 's stag criterion Had primary melanoma completely resect adequate surgical margin undergone operation positive regional lymph node within 84 day study start Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) score 0 1 Adequate hepatic , renal bone marrow function define study parameter obtain within 4 week prior study start For female subject childbearing potential male participant female sexual partner childbearing potential , agree use acceptable method contraception least 2 week prior study start continue least 6 month last dose study medication , longer dictate local regulation Mucous membrane melanoma ocular melanoma Known hypersensitivity component study drug ( include acetaminophen ) , analogs Evidence distant nonregional lymph node metastases intransit metastasis Disease completely surgically resect Prior malignancy within past 5 year surgically cure nonmelanoma skin cancer cervical carcinoma situ Severe cardiovascular disease , i.e . arrhythmia , require chronic treatment , congestive heart failure symptomatic ischemic heart disease Hepatic decompensation Thyroid dysfunction responsive therapy Uncontrolled diabetes mellitus Clinically active autoimmune disease Clinically active and/or uncontrolled infection , include active hepatitis Human immunodeficiency virus ( HIV ) History neuropsychiatric disorder require hospitalization Actively abuse alcohol drug Pregnant , lactating , reproductive potential use effective mean contraception Medical condition require chronic systemic corticosteroid Received experimental therapy within 30 day prior enrol study Received prior chemotherapy , immunotherapy , hormonal radiation therapy melanoma Previously receive interferonÎ± reason Known serious hypersensitivity reaction PEGIFN interferon alfa2b</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>